Analysts have been eager to weigh in on the Healthcare sector with new ratings on Conmed (CNMD – Research Report), AbbVie (ABBV – Research Report) and Nurix Therapeutics (NRIX – Research Report).
Conmed (CNMD)
Wells Fargo analyst Vik Chopra maintained a Hold rating on Conmed yesterday and set a price target of $98.00. The company’s shares closed last Tuesday at $80.36, close to its 52-week low of $74.67.
According to TipRanks.com, Chopra is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Conmed with a $109.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
AbbVie (ABBV)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie, with a price target of $200.00. The company’s shares closed last Tuesday at $170.14.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $180.86, which is a 6.6% upside from current levels. In a report issued on March 27, Barclays also maintained a Buy rating on the stock with a $195.00 price target.
Nurix Therapeutics (NRIX)
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics, with a price target of $20.00. The company’s shares closed last Tuesday at $17.48.
According to TipRanks.com, Archila is a 4-star analyst with an average return of
Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $24.00, which is a 72.0% upside from current levels. In a report issued on March 25, Robert W. Baird also maintained a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNMD:
